Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (250)	7/30/2002 1:44:47 PM
From: scaram(o)uche	Read Replies (2) of 631

(Bad) luck of the draw, then?? Celltech deserves better news. This is the sort of result that I've always expected of anti-TNF, anti-IL-1, etc........ good, but hardly stupefying. Enbrel results have always been much better than I expected. The Amgen IL-1RA yielded about what I expected from it. I still believe that sub-depleting doses of amevive or MEDI-507, administered for prolonged periods, are a good bet. And I still believe in the anti-integrins, if there is no evidence of disease that is more intense than pre-treat, once discontinued. For antegren and MS, there would, of course, be more tolerance re. potential for rebound.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next